---
title: "Qulipta (atogepant) in preventive treatment of migraine: Clinical trials questions"
description: "Clinical trials questions on Qulipta (atogepant) in preventive treatment of migraine, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results and Comparative studies. Questions: How much does Qulipta reduce monthly migraine days in episodic migraine (ADVANCE)? Did every Qulipta dose reduce episodic migraine days vs placebo? How much does Qulipta reduce monthly migraine days in chronic migraine (PROGRESS)? What share of Qulipta episodic migraine patients had 50% fewer migraine days (ADVANCE)? 9 further questions follow. 13 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Qulipta (atogepant) in preventive treatment of migraine: Clinical trials questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Qulipta](https://www.rxabbvie.com/pdf/qulipta_pi.pdf)

## Study results

<a id="qulipta-episodic-migraine-days"></a>

### How much does Qulipta reduce monthly migraine days in episodic migraine (ADVANCE)?

Applies to: Preventive treatment of episodic migraine in adults

> “Two randomized, double-blind, placebo-controlled, parallel-group studies that evaluated the efficacy and safety of QULIPTA for 12 weeks in patients who were experiencing 4 to 14 migraine days per month. Patients in trials were 88% female, 80% White, 17% Black, and 12% Hispanic or Latino ethnicity, and the mean age at study entry was 41 years (range 18-74 years). The studies excluded patients with myocardial infarction, stroke, or transient ischemic attacks within 6 months prior to screening.<sup>1,2</sup>”

Source: [QULIPTA: Powerful Reductions & Continuous Control – QULIPTA® HCP, captured 2026-11-14](https://www.quliptahcp.com/powerful-reductions-continuous-control#:~:text=Two%20randomized%2C%20double%2Dblind%2C%20placebo%2Dcontrolled%2C%20parallel%2Dgroup,within%206%20months%20prior%20to)

On the page, select: Episodic migraine study design (ADVANCE; Phase 2b/3 dose-finding study)

> “Patients saw 54% mean MMD reduction across 12 weeks with QULIPTA 60 mg<sup>1</sup>”

Source: [QULIPTA: Powerful Reductions & Continuous Control – QULIPTA® HCP, captured 2026-11-14](https://www.quliptahcp.com/powerful-reductions-continuous-control#:~:text=Patients%20saw%2054%25%20mean%20MMD%20reduction%20across%2012%20weeks%20with%20QULIPTA%2060)

> “Primary endpoint:
>
> Mean MMD reduction across 12 weeks<sup>1</sup>
>
> MMD reduction across 12 weeks with QULIPTA 60 mg (4.2 fewer MMD from 7.8 baseline) (n=222; P<0.001) vs 33% with placebo (2.5 fewer MMD from 7.5 baseline) (n=214)<sup>1</sup>”

Source: [QULIPTA: Powerful Reductions & Continuous Control – QULIPTA® HCP, captured 2026-11-14](https://www.quliptahcp.com/powerful-reductions-continuous-control#:~:text=Primary%20endpoint%3A,fewer%20MMD%20from%207.5%20baseline%29)

> “QULIPTA 30 mg: 49% MMD reduction (3.9 fewer MMD from 7.9 baseline) (n=223; P<0.001)<sup>1</sup>
> QULIPTA 10 mg: 49% MMD reduction (3.7 fewer MMD from 7.5 baseline) (n=214; P<0.001)<sup>1</sup>”

Source: [QULIPTA: Powerful Reductions & Continuous Control – QULIPTA® HCP, captured 2026-11-14](https://www.quliptahcp.com/powerful-reductions-continuous-control#:~:text=QULIPTA%2030%20mg%3A%2049%25%20MMD,MMD%20from%207.5%20baseline%29%20%28n%3D214%3B)

> “EM primary endpoint: Significant -4.2 monthly migraine day reduction from 7.8 baseline (n=222; P<0.001) vs -2.5 from 7.5 baseline for placebo (n=214)<sup>1</sup>*”

Source: [QULIPTA: Migraine Preventive Medication - QULIPTA® (atogepant) HCP, captured 2026-11-14](https://www.quliptahcp.com/#:~:text=EM%20primary%20endpoint%3A%20Significant%20%2D4.2,from%207.5%20baseline%20for%20placebo)

> “*Data from Phase 3 ADVANCE EM pivotal study.”

Source: [QULIPTA: Migraine Preventive Medication - QULIPTA® (atogepant) HCP, captured 2026-11-14](https://www.quliptahcp.com/#:~:text=%2AData%20from%20Phase%203%20ADVANCE%20EM%20pivotal%20study.)

Note: The HCP page cites the Prescribing Information (its reference 1) for these results; the Prescribing Information reports the trial as Study 1 (NCT03777059), with the same group sizes and baselines. The design passage describes the two episodic migraine studies together.

<a id="qulipta-episodic-dose-comparison"></a>

### Did every Qulipta dose reduce episodic migraine days vs placebo?

Applies to: Preventive treatment of episodic migraine in adults

> “In Study 1 (NCT03777059), 910 patients were randomized 1:1:1:1 to receive QULIPTA 10 mg 
> (N = 222), QULIPTA 30 mg (N = 230), QULIPTA 60 mg (N = 235), or placebo (N = 223), once 
> daily for 12 weeks.”

Source: [QULIPTA: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=12)

> “In Study 2 (NCT02848326), 652 patients were randomized 1:2:2:2 to receive 
> QULIPTA 10 mg (N = 94), QULIPTA 30 mg (N = 185), QULIPTA 60 mg (N = 187), or placebo 
> (N = 186), once daily for 12 weeks.”

Source: [QULIPTA: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=12)

> “Table 3: Efficacy Endpoints in Study 1 
>
> QULIPTA 
> 10 mg 
> N=214 
> QULIPTA 
> 30 mg 
> N=223 
> QULIPTA 
> 60 mg 
> N=222 
> Placebo 
>
> N=214 
> Monthly Migraine Days (MMD) across 12 weeks 
> Baseline 
> 7.5 
> 7.9 
> 7.8 
> 7.5 
> Mean change from baseline 
> -3.7 
> -3.9 
> -4.2 
> -2.5 
> Difference from placebo 
> -1.2 
> -1.4 
> -1.7 
>
> p-value 
> <0.001 
> <0.001 
> <0.001”

Source: [QULIPTA: Prescribing information, page 13, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=13)

> “In Study 2, there was a significantly greater reduction in mean monthly migraine days across the 
> 12-week treatment period in all three QULIPTA treatment groups, compared with placebo, as 
> summarized in Table 4.”

Source: [QULIPTA: Prescribing information, page 15, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=15)

> “Table 4: Efficacy Endpoints in Study 2 
>
> QULIPTA 
> 10 mg 
> N=92 
> QULIPTA 
> 30 mg 
> N=182 
> QULIPTA 
> 60 mg 
> N=177 
> Placebo 
>
> N=178 
> Monthly Migraine Days (MMD) across 12 weeks 
> Baseline 
> 7.6 
> 7.6 
> 7.7 
> 7.8 
> Mean change from baseline 
> -4.0 
> -3.8 
> -3.6 
> -2.8 
> Difference from placebo 
> -1.1 
> -0.9 
> -0.7 
>
> p-value 
> 0.024 
> 0.039 
> 0.039”

Source: [QULIPTA: Prescribing information, page 15, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=15)

Note: Table columns are QULIPTA 10 mg, QULIPTA 30 mg, QULIPTA 60 mg, and placebo, in that order; each row lists its values in that order.

<a id="qulipta-chronic-migraine-days"></a>

### How much does Qulipta reduce monthly migraine days in chronic migraine (PROGRESS)?

Applies to: Preventive treatment of chronic migraine in adults

> “A randomized, double-blind, placebo-controlled, parallel-group study that evaluated the efficacy and safety of QULIPTA for 12 weeks in patients who were experiencing 15 or more migraine days per month. Patients in trials were 87% female, 60% White, 3% Black, 36% Asian, and 4% Hispanic or Latino ethnicity, and the mean age at study entry was 42 years (range 18-74 years). A subset of patients (11%) was allowed to use 1 concomitant migraine preventive medication. The study excluded patients with myocardial infarction, stroke, or transient ischemic attacks within 6 months prior to screening.<sup>1,7</sup>”

Source: [QULIPTA: Powerful Reductions & Continuous Control – QULIPTA® HCP, captured 2026-11-14](https://www.quliptahcp.com/powerful-reductions-continuous-control#:~:text=A%20randomized%2C%20double%2Dblind%2C%20placebo%2Dcontrolled%2C%20parallel%2Dgroup,within%206%20months%20prior%20to)

On the page, select: Chronic migraine study design (PROGRESS)

> “Primary endpoint: Mean MMD reduction across 12 weeks<sup>1</sup>
>
> QULIPTA 60 mg
> -6.9 days from 19.2 baseline MMD
> (n=256) (P<0.001)<sup>1</sup>
>
> vs
>
> Placebo
> -5.1 days from 18.9 baseline MMD
> (n=246)<sup>1</sup>”

Source: [QULIPTA: Powerful Reductions & Continuous Control – QULIPTA® HCP, captured 2026-11-14](https://www.quliptahcp.com/powerful-reductions-continuous-control#:~:text=Migraine%20Day%20Reductions-,Primary%20endpoint%3A%20Mean%20MMD%20reduction%20across%2012,days%20from%2018.9%20baseline%20MMD)

> “CM primary endpoint: Significant -6.9 monthly migraine day reduction from 19.2 baseline (n=256; P<0.001) vs -5.1 from 18.9 baseline for placebo (n=246)<sup>1†</sup>”

Source: [QULIPTA: Migraine Preventive Medication - QULIPTA® (atogepant) HCP, captured 2026-11-14](https://www.quliptahcp.com/#:~:text=CM%20primary%20endpoint%3A%20Significant%20%2D6.9,from%2018.9%20baseline%20for%20placebo)

> “<sup>†</sup>Data from Phase 3 PROGRESS CM pivotal study.”

Source: [QULIPTA: Migraine Preventive Medication - QULIPTA® (atogepant) HCP, captured 2026-11-14](https://www.quliptahcp.com/#:~:text=from%20Phase%203%20PROGRESS%20CM%20pivotal%20study.)

> “Table 5: Efficacy Endpoints in Study 3 
>
> QULIPTA 60 mg QD 
> N=256 
> Placebo 
> N=246 
> Monthly Migraine Days (MMD) across 12 weeks 
> Baseline 
> 19.2 
> 18.9 
> Mean change from baseline 
> -6.9 
> -5.1 
> Difference from placebo 
> -1.8 
>
> p-value 
> <0.001”

Source: [QULIPTA: Prescribing information, page 17, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=17)

Note: The HCP page cites the Prescribing Information (its reference 1) for these results; the Prescribing Information reports the trial as Study 3 (NCT03855137). Table 5 columns are QULIPTA 60 mg and placebo, in that order; each row lists its values in that order.

<a id="qulipta-episodic-responder-rate"></a>

### What share of Qulipta episodic migraine patients had 50% fewer migraine days (ADVANCE)?

Applies to: Preventive treatment of episodic migraine in adults

> “Secondary endpoint:
>
> Percentage of patients who achieved ≥50% MMD reduction across 12 weeks<sup>1</sup>
>
> WEEKS 1-12
>
> with QULIPTA 60 mg
>
> 61
> <sup>%</sup>
>
> (n=222; P<0.001) vs 29% with placebo (n=214)<sup>1</sup>
>
> Similar 12-week average results were seen with other doses<sup>1</sup>:
>
> 59% for QULIPTA 30 mg (n=223; P<0.001) 
> 56% for QULIPTA 10 mg (n=214; P<0.001)”

Source: [QULIPTA: Powerful Reductions & Continuous Control – QULIPTA® HCP, captured 2026-11-14](https://www.quliptahcp.com/powerful-reductions-continuous-control#:~:text=Secondary%20endpoint%3A,QULIPTA%2010%20mg%20%28n%3D214%3B%20P%3C0.001%29)

> “Two randomized, double-blind, placebo-controlled, parallel-group studies that evaluated the efficacy and safety of QULIPTA for 12 weeks in patients who were experiencing 4 to 14 migraine days per month.”

Source: [QULIPTA: Powerful Reductions & Continuous Control – QULIPTA® HCP, captured 2026-11-14](https://www.quliptahcp.com/powerful-reductions-continuous-control#:~:text=Two%20randomized%2C%20double%2Dblind%2C%20placebo%2Dcontrolled%2C%20parallel%2Dgroup,14%20migraine%20days%20per%20month.)

On the page, select: Episodic migraine study design (ADVANCE; Phase 2b/3 dose-finding study)

> “Table 3: Efficacy Endpoints in Study 1 
>
> QULIPTA 
> 10 mg 
> N=214 
> QULIPTA 
> 30 mg 
> N=223 
> QULIPTA 
> 60 mg 
> N=222 
> Placebo 
>
> N=214”

Source: [QULIPTA: Prescribing information, page 13, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=13)

> “≥ 50% MMD Responders across 12 weeks 
> % Responders 
> 56 
> 59 
> 61 
> 29 
> Difference from placebo (%) 
> 27 
> 30 
> 32 
>
> p-value 
> <0.001 
> <0.001 
> <0.001”

Source: [QULIPTA: Prescribing information, page 13, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=13)

Note: The HCP page cites the Prescribing Information (its reference 1) for these results; the Prescribing Information reports the trial as Study 1; the last two passages are from its Table 3. Table columns are QULIPTA 10 mg, QULIPTA 30 mg, QULIPTA 60 mg, and placebo, in that order; each row lists its values in that order.

<a id="qulipta-chronic-responder-rate"></a>

### How many chronic migraine patients had 50% fewer migraine days on Qulipta?

Applies to: Preventive treatment of chronic migraine in adults

> “Study 3 (NCT03855137) included randomization of patients to QULIPTA 60 mg once daily 
> (N = 262) or placebo (N = 259) for 12 weeks.”

Source: [QULIPTA: Prescribing information, page 17, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=17)

> “Table 5: Efficacy Endpoints in Study 3 
>
> QULIPTA 60 mg QD 
> N=256 
> Placebo 
> N=246”

Source: [QULIPTA: Prescribing information, page 17, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=17)

> “≥ 50% MMD Responders across 12 weeks 
> % Responders 
> 41 
> 26 
> Difference from placebo (%) 
> 15 
>
> p-value 
> <0.001”

Source: [QULIPTA: Prescribing information, page 18, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=18)

Note: Table 5 columns are QULIPTA 60 mg and placebo, in that order; each row lists its values in that order.

<a id="qulipta-episodic-zero-migraine-days"></a>

### How many episodic migraine patients had no migraine days on Qulipta (ADVANCE)?

Applies to: Preventive treatment of episodic migraine in adults

> “Percentage of patients who achieved 100% MMD reduction across 12 weeks<sup>4</sup>
>
> WEEKS 1-12
>
> with QULIPTA 60 mg
>
> 8
> <sup>%</sup>
>
> (n=222) vs 1% with placebo (n=214)<sup>4</sup>
>
> Similar 12-week average results were seen with other doses<sup>4</sup>:
>
> 5% for QULIPTA 30 mg (n=223)
> 8% for QULIPTA 10 mg (n=214)”

Source: [QULIPTA: Powerful Reductions & Continuous Control – QULIPTA® HCP, captured 2026-11-14](https://www.quliptahcp.com/powerful-reductions-continuous-control#:~:text=Percentage%20of%20patients%20who%20achieved%20100%25,for%20QULIPTA%2010%20mg%20%28n%3D214%29)

> “LIMITATIONS: The additional endpoints were prespecified, non-ranked endpoints and were not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.”

Source: [QULIPTA: Powerful Reductions & Continuous Control – QULIPTA® HCP, captured 2026-11-14](https://www.quliptahcp.com/powerful-reductions-continuous-control#:~:text=LIMITATIONS%3A%20The%20additional%20endpoints%20were%20prespecified%2C%20non%2Dranked%20endpoints%20and%20were%20not%20adjusted%20for%20multiplicity.%20Therefore%2C%20treatment%20differences%20cannot%20be%20regarded%20as%20statistically%20significant.,-STUDY%20DESIGN)

Note: The page labels this an additional endpoint and reports it for the ADVANCE episodic migraine trial; a 100% reduction in monthly migraine days means no migraine days across the 12 weeks. The page cites AbbVie data on file (its reference 4) for these figures; the Prescribing Information does not report this endpoint.

<a id="qulipta-episodic-acute-medication-days"></a>

### Does Qulipta reduce acute medication use days in episodic migraine?

Applies to: Preventive treatment of episodic migraine in adults

> “The efficacy of QULIPTA for the preventive treatment of episodic migraine in adults was 
> demonstrated in two randomized, multicenter, double-blind, placebo-controlled studies (Study 1 
> and Study 2).”

Source: [QULIPTA: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=12)

> “Table 3: Efficacy Endpoints in Study 1 
>
> QULIPTA 
> 10 mg 
> N=214 
> QULIPTA 
> 30 mg 
> N=223 
> QULIPTA 
> 60 mg 
> N=222 
> Placebo 
>
> N=214”

Source: [QULIPTA: Prescribing information, page 13, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=13)

> “Monthly Acute Medication Use Days across 12 weeks 
> Baseline 
> 6.6 
> 6.7 
> 6.9 
> 6.5 
> Mean change from baseline 
> -3.7 
> -3.7 
> -3.9 
> -2.4 
> Difference from placebo 
> -1.3 
> -1.3 
> -1.5 
>
> p-value 
> <0.001 
> <0.001 
> <0.001”

Source: [QULIPTA: Prescribing information, page 13, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=13)

Note: Table columns are QULIPTA 10 mg, QULIPTA 30 mg, QULIPTA 60 mg, and placebo, in that order; each row lists its values in that order.

<a id="qulipta-chronic-acute-medication-days"></a>

### Does Qulipta reduce acute medication use days in chronic migraine?

Applies to: Preventive treatment of chronic migraine in adults

> “The efficacy of QULIPTA for the preventive treatment of chronic migraine in adults was 
> demonstrated in a randomized, multicenter, double-blind, placebo-controlled study (Study 3).”

Source: [QULIPTA: Prescribing information, page 17, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=17)

> “Table 5: Efficacy Endpoints in Study 3 
>
> QULIPTA 60 mg QD 
> N=256 
> Placebo 
> N=246”

Source: [QULIPTA: Prescribing information, page 17, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=17)

> “Monthly Acute Medication Use Days across 12 weeks 
> Baseline 
> 15.5 
> 15.4 
> Mean change from baseline 
> -6.2 
> -4.1 
> Difference from placebo 
> -2.1 
>
> p-value 
> <0.001”

Source: [QULIPTA: Prescribing information, page 18, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=18)

Note: Table 5 columns are QULIPTA 60 mg and placebo, in that order; each row lists its values in that order.

<a id="qulipta-episodic-daily-activities"></a>

### Does Qulipta improve daily activities in episodic migraine (ADVANCE)?

Applies to: Preventive treatment of episodic migraine in adults

> “EM secondary endpoint: Change from baseline in mean monthly AIM-D PDA domain score across a 12-week treatment period
>
> -9.4 point improvement from 15.9 baseline for QULIPTA 60 mg (n=222; P<0.001) vs -6.1 from 15.2 baseline for placebo (n=214)<sup>1</sup>*”

Source: [QULIPTA: Migraine Preventive Medication - QULIPTA® (atogepant) HCP, captured 2026-11-14](https://www.quliptahcp.com/#:~:text=EM%20secondary%20endpoint%3A%20Change%20from,from%2015.2%20baseline%20for%20placebo)

> “QULIPTA 30 mg: -8.6 point improvement from baseline 16.9 (N=223; P<0.001)
> QULIPTA 10 mg: -7.3 point improvement from baseline 15.5 (N=214). The 10 mg results were not statistically significant”

Source: [QULIPTA: Daily Activities & Head-to-Head Data – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/daily-activities-and-head-to-head-data#:~:text=QULIPTA%2030%20mg%3A%20%2D8.6%20point,results%20were%20not%20statistically%20significant)

> “AIM-D is an 11-item questionnaire designed to measure activity impairment attributed to migraine in the past 24 hours and consists of 2 domains: PDA (7 items) and PI (4 items). Participants responded to items using a 6-point scale ranging from “Not difficult at all” to “I could not do it at all.” Scores are transformed to a 0-100 scale. Higher scores indicate greater impact of migraine, and reductions from baseline indicate improvement.<sup>2,3</sup>”

Source: [QULIPTA: Daily Activities & Head-to-Head Data – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/daily-activities-and-head-to-head-data#:~:text=AIM%2DD%20is%20an%2011%2Ditem%20questionnaire,and%20reductions%20from%20baseline%20indicate)

> “*Data from Phase 3 ADVANCE EM pivotal study.”

Source: [QULIPTA: Migraine Preventive Medication - QULIPTA® (atogepant) HCP, captured 2026-11-14](https://www.quliptahcp.com/#:~:text=%2AData%20from%20Phase%203%20ADVANCE%20EM%20pivotal%20study.)

> “Table 3: Efficacy Endpoints in Study 1 
>
> QULIPTA 
> 10 mg 
> N=214 
> QULIPTA 
> 30 mg 
> N=223 
> QULIPTA 
> 60 mg 
> N=222 
> Placebo 
>
> N=214”

Source: [QULIPTA: Prescribing information, page 13, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=13)

> “AIM-D PDA Domain** across 12 weeks 
> Baseline 
> 15.5 
> 16.9 
> 15.9 
> 15.2 
> Mean change from baseline 
> -7.3 
> -8.6 
> -9.4 
> -6.1 
> Difference from placebo 
> -1.2 
> -2.5 
> -3.3 
>
> p-value 
> NS<sup>†</sup> 
> <0.001 
> <0.001”

Source: [QULIPTA: Prescribing information, page 14, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=14)

> “<sup>†</sup>Not statistically significant (NS)”

Source: [QULIPTA: Prescribing information, page 14, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=14)

Note: The HCP page cites the Prescribing Information (its reference 1) for these results; the Prescribing Information reports the trial as Study 1; the last three passages are from its Table 3. Table columns are QULIPTA 10 mg, QULIPTA 30 mg, QULIPTA 60 mg, and placebo, in that order; each row lists its values in that order.

<a id="qulipta-chronic-daily-activities"></a>

### Does Qulipta improve daily activities in chronic migraine (AIM-D PDA)?

Applies to: Preventive treatment of chronic migraine in adults

> “The efficacy of QULIPTA for the preventive treatment of chronic migraine in adults was 
> demonstrated in a randomized, multicenter, double-blind, placebo-controlled study (Study 3).”

Source: [QULIPTA: Prescribing information, page 17, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=17)

> “Table 5: Efficacy Endpoints in Study 3 
>
> QULIPTA 60 mg QD 
> N=256 
> Placebo 
> N=246”

Source: [QULIPTA: Prescribing information, page 17, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=17)

> “AIM-D PDA Domain** across 12 weeks 
> Baseline 
> 31.2 
> 29.5 
> Mean change from baseline 
> -12.8 
> -9.4 
> Difference from placebo 
> -3.4 
>
> p-value 
> <0.001”

Source: [QULIPTA: Prescribing information, page 18, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=18)

> “** Activity Impairment in Migraine-Diary Performance of Daily Activities domain score”

Source: [QULIPTA: Prescribing information, page 18, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=18)

Note: Table 5 columns are QULIPTA 60 mg and placebo, in that order; each row lists its values in that order.

<a id="qulipta-medication-overuse"></a>

### Was Qulipta studied in chronic migraine with medication overuse headache?

Applies to: Preventive treatment of chronic migraine in adults

> “Patients with medication overuse headache also were enrolled.”

Source: [QULIPTA: Prescribing information, page 17, captured 2026-11-14](https://www.rxabbvie.com/pdf/qulipta_pi.pdf#page=17)

> “MEDICATION OVERUSE
>
> Nearly two-thirds of patients who were studied overused acute medication<sup>6</sup>”

Source: [QULIPTA: Powerful Reductions & Continuous Control – QULIPTA® HCP, captured 2026-11-14](https://www.quliptahcp.com/powerful-reductions-continuous-control#:~:text=MEDICATION%20OVERUSE,who%20were%20studied%20overused%20acute)

Note: Both passages describe the chronic migraine trial (Study 3 in the label, PROGRESS on the HCP page). The HCP page cites AbbVie data on file (its reference 6) for the medication overuse figure.

## Comparative studies

<a id="qulipta-temple-side-effects"></a>

### Qulipta vs topiramate: how did side effects compare (TEMPLE)?

> “A global, multicenter, randomized, double-blind, double-dummy (matching placebos), parallel-group, active-controlled, 24-week Phase 3b trial comparing the tolerability, safety, and efficacy of QULIPTA 60 mg once daily and topiramate at the highest tolerated dose (50, 75, or 100 mg/day) in adults with episodic or chronic migraine who were eligible for conventional preventive migraine treatment.<sup>3</sup>”

Source: [QULIPTA: Head-to-Head Safety Data for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/head-to-head-safety-data#:~:text=A%20global%2C%20multicenter%2C%20randomized%2C%20double%2Dblind%2C,eligible%20for%20conventional%20preventive%20migraine)

On the page, select: TEMPLE study design

> “Treatment-emergent adverse events ≥5% in either trial group at any time during the double-blind treatment period<sup>1</sup>*
>
>  	QULIPTA 60 MG QD
> (N=273)
> 	TOPIRAMATE<sup>†</sup>
> (N=267)
>
> PARESTHESIA	5.1<sup>%</sup>	41.2<sup>%</sup>
> NAUSEA	19.8<sup>%</sup>	16.5<sup>%</sup>
> FATIGUE	15.4<sup>%</sup>	14.2<sup>%</sup>
> NASOPHARYNGITIS	11.0<sup>%</sup>	12.7<sup>%</sup>
> DIZZINESS	7.7<sup>%</sup>	10.5<sup>%</sup>
> DECREASED APPETITE	12.5<sup>%</sup>	10.1<sup>%</sup>
> DISTURBANCE IN ATTENTION	7.0<sup>%</sup>	9.7<sup>%</sup>
> HYPOESTHESIA	0.7<sup>%</sup>	5.6<sup>%</sup>
> CONSTIPATION	9.9<sup>%</sup>	4.9<sup>%</sup>”

Source: [QULIPTA: Head-to-Head Safety Data for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/head-to-head-safety-data#:~:text=Treatment%2Demergent%20adverse%20events%20%E2%89%A55%25%20in,CONSTIPATION)

> “88.8% of patients on topiramate (237/267) and 76.9% of patients on QULIPTA (210/273) experienced treatment-emergent adverse events<sup>1*</sup>
>
> *Based on the safety population (N=540) which included all subjects who received at least 1 dose of study treatment during the double-blind treatment period.<sup>1</sup>”

Source: [QULIPTA: Head-to-Head Safety Data for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/head-to-head-safety-data#:~:text=88.8%25%20of%20patients%20on%20topiramate,treatment%20during%20the%20double%2Dblind%20treatment)

> “<sup>†</sup>Topiramate dosing: 25 mg starting daily dose was titrated up to the highest tolerated daily dose of 50 mg, 75 mg, or 100 mg.<sup>3</sup>”

Source: [QULIPTA: Head-to-Head Safety Data for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/head-to-head-safety-data#:~:text=dosing%3A%2025%20mg%20starting%20daily,mg%2C%2075%20mg%2C%20or%20100)

Note: Table columns are QULIPTA 60 mg once daily (N=273) and topiramate (N=267), in that order. The HCP page cites AbbVie data on file for these results.

<a id="qulipta-temple-weight"></a>

### Qulipta vs topiramate: how did weight change (TEMPLE)?

> “Patients experienced similar weight decreases between QULIPTA and topiramate at the end of the double-blind treatment period<sup>2‡</sup>:
>
> In the overall safety population<sup>§</sup> the mean change from baseline weight for patients were<sup>¶</sup>:
>
> QULIPTA 60 mg (n=270):
> -3.3 lb from baseline 157.8 lb
> Topiramate (n=262):
> -4.3 lb from baseline 159 lb”

Source: [QULIPTA: Head-to-Head Safety Data for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/head-to-head-safety-data#:~:text=Patients%20experienced%20similar%20weight%20decreases,lb%20from%20baseline%20159%20lb)

> “PERCENTAGE of
> patients with ≥5%
> WEIGHT DECREASE
>
>
> anytime during the double-blind treatment period*
>
> 	28<sup>%</sup>
> (75/270)	29<sup>%</sup>
> (76/262)
> CHANGE IN WEIGHT (lb)
> from baseline in
> patients with ≥5%
> WEIGHT DECREASE
>
>
> at the end of the double-blind treatment period*
>
> 	-11.6 lb
> Baseline: 159.5 lb<sup>†</sup>	-12.4 lb
> Baseline: 159.1 lb<sup>†</sup>”

Source: [QULIPTA: Head-to-Head Safety Data for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/head-to-head-safety-data#:~:text=PERCENTAGE%20of,Baseline%3A%20159.1)

> “NOTE: 5.6% of QULIPTA patients compared to 4.6% of topiramate patients experienced a ≥5% weight gain at any time during the DB treatment period.<sup>4</sup>”

Source: [QULIPTA: Head-to-Head Safety Data for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/head-to-head-safety-data#:~:text=NOTE%3A%205.6%25%20of%20QULIPTA%20patients,time%20during%20the%20DB%20treatment)

> “<sup>‡</sup>The end of double-blind treatment period is defined as the scheduled subsequent visit after a subject stops taking the study drug within the double-blind treatment period.<sup>2</sup>
>
> <sup>§</sup>Includes subjects in the safety population with non-missing baseline weight value and post-baseline weight value at the end of the double-blind treatment period.<sup>2</sup>
>
> <sup>¶</sup>These measurements were converted from kilograms to pounds. For QULIPTA, the baseline weight was 71.6 kg with a reduction of -1.5 kg. For topiramate, the baseline weight was 72.1 kg with a reduction of -1.9 kg.<sup>2</sup>”

Source: [QULIPTA: Head-to-Head Safety Data for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/head-to-head-safety-data#:~:text=end%20of%20double%2Dblind%20treatment%20period,with%20a%20reduction%20of%20%2D1.9)

> “*The end of the double-blind treatment period is defined as the scheduled subsequent visit after a subject stops taking the study drug within the double-blind treatment period.<sup>2</sup>
>
> <sup>†</sup>Baseline weight measurements were converted from kilograms to pounds. Patients on QULIPTA who experienced at least 5% weight decrease had a baseline weight of 72.4 kg with a reduction of -5.3 kg. Patients on topiramate who experienced at least 5% weight decrease had a baseline weight of 72.2 kg with a reduction of -5.6 kg.<sup>2</sup>”

Source: [QULIPTA: Head-to-Head Safety Data for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/head-to-head-safety-data#:~:text=%2AThe%20end%20of%20the%20double%2Dblind,with%20a%20reduction%20of%20%2D5.6)

Note: In the table, the first value in each row is for QULIPTA 60 mg and the second for topiramate. The table's * and † marks are defined in the last passage; the ‡, §, and ¶ marks of the first passage are defined in the passage before it.

## Related pages
- [Medical information: Qulipta (atogepant): Preventive treatment of migraine](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine)
- [Indication](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/safety)
- [Specific populations](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/access-and-coverage)
